Action Takeda Pharmaceutical - 0RN3

Takeda Pharmaceutical Co (0RN3) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

49,35

( - )

Prix Achat

49,35

Prix Vente

49,35

Volume échangé

0,00

0,00 Fourchette du Jour 0,00

49,35 Plage de 52 semaines 49,35

Clôture Veille

49,35

Ouverture

Dernière Transaction

(O)

Dernière heure de transaction

Volume moyen (3 m)

0,00

Volume financier

VWAP

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR...

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR...

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent...

Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community

Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community PR Newswire DUBAI, UAE, June 9, 2021...

Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community

Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community PR Newswire DUBAI, UAE, June 9, 2021...

Takeda Pharmaceutical Company Ltd Confirmation of post-offer intention statements

Takeda Pharmaceutical Company Ltd 08 January 2020 Better Health, Brighter Future News Release THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO...

Morgan Stanley & Co. LLC Form 8.5 (EPT/RI) - Replacement of Takeda

Morgan Stanley & Co. LLC 14 January 2019 AMENDMENT Section (2a) FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH...

Takeda Pharmaceutical Company Ltd Statement re Applicable Exchange Rate

Takeda Pharmaceutical Company Ltd 11 January 2019 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN...

Morgan Stanley Form 8.5 (EPT/NON-RI) - Replacement of Takeda

Morgan Stanley 10 January 2019 AMMENT Section (2a) & (3a) FORM 8.5 (EPT/NON-RI) PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN...

Morgan Stanley & Co. Int'l plc Form 8.5 (EPT/RI) - Replacement of Takeda

Morgan Stanley & Co. Int'l plc 10 January 2019 AMENDMENT Section (2a) FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL...

Période	Ouver.	Haut	Bas
1	0	0	0	DE
4	0	0	0	DE
12	49.35	49.35	49.35	DE
26	49.35	49.35	49.35	DE
52	49.35	49.35	49.35	DE
156	49.35	49.35	49.35	DE
260	49.35	49.35	49.35	DE

0RN3 - Frequently Asked Questions (FAQ)

What is the current Takeda Pharmaceutical Co share price?

The current share price of Takeda Pharmaceutical Co is 49,35 €

What is the 1 year trading range for Takeda Pharmaceutical Co share price?

Takeda Pharmaceutical Co has traded in the range of 49,35 € to 49,35 € during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Takeda Pharmaceutical Co (0RN3)

Takeda Pharmaceutical Co (0RN3) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

0RN3 Dernières nouvelles

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community

Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community

Takeda Pharmaceutical Company Ltd Confirmation of post-offer intention statements

Morgan Stanley & Co. LLC Form 8.5 (EPT/RI) - Replacement of Takeda

Takeda Pharmaceutical Company Ltd Statement re Applicable Exchange Rate

Morgan Stanley Form 8.5 (EPT/NON-RI) - Replacement of Takeda

Morgan Stanley & Co. Int'l plc Form 8.5 (EPT/RI) - Replacement of Takeda

0RN3 - Frequently Asked Questions (FAQ)

0RN3 Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Takeda Pharmaceutical Co (0RN3)

Takeda Pharmaceutical Co (0RN3) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

0RN3 Dernières nouvelles

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community

Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community

Takeda Pharmaceutical Company Ltd Confirmation of post-offer intention statements

Morgan Stanley & Co. LLC Form 8.5 (EPT/RI) - Replacement of Takeda

Takeda Pharmaceutical Company Ltd Statement re Applicable Exchange Rate

Morgan Stanley Form 8.5 (EPT/NON-RI) - Replacement of Takeda

Morgan Stanley & Co. Int'l plc Form 8.5 (EPT/RI) - Replacement of Takeda

0RN3 - Frequently Asked Questions (FAQ)

0RN3 Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités